Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
April 27, 2023 07:01 ET
|
Autolus Therapeutics plc
LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics to Host Virtual Capital Markets Day
April 25, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a...
Post Holdings Reports Results for the First Quarter of Fiscal Year 2023; Raises Fiscal Year 2023 Outlook
February 02, 2023 17:00 ET
|
Post Holdings, Inc.
ST. LOUIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the first fiscal quarter ended December 31, 2022. ...
Post Holdings Reports Results for the Fourth Quarter and Fiscal Year 2022
November 17, 2022 17:00 ET
|
Post Holdings, Inc.
ST. LOUIS, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the fourth fiscal quarter and fiscal year ended...
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:10 ET
|
Vaxcyte, Inc.
-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive...
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
October 24, 2022 06:30 ET
|
Vaxcyte, Inc.
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2mcg PCV Dose Met or...
Trillium Gold Provides Update on Newman Todd and Gold Centre Projects
August 11, 2022 07:00 ET
|
Trillium Gold Mines Inc.
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trillium Gold Mines Inc. (TSXV:TGM, OTCQX:TGLDF, FRA:0702) (“Trillium Gold” or the “Company”) is pleased to provide an update on the...
Post Holdings Reports Results for the Third Quarter of Fiscal Year 2022; Raises Fiscal Year 2022 Outlook
August 04, 2022 17:00 ET
|
Post Holdings, Inc.
ST. LOUIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the third fiscal quarter ended June 30, 2022. ...
Post Holdings Reports Results for the Second Quarter of Fiscal Year 2022
May 05, 2022 17:00 ET
|
Post Holdings, Inc.
ST. LOUIS, May 05, 2022 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the second fiscal quarter ended March 31, 2022. ...
BellRing Brands Reports Results for the First Quarter of Fiscal Year 2022
February 03, 2022 17:00 ET
|
BellRing Brands, Inc.
ST. LOUIS, Feb. 03, 2022 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global convenient nutrition category, today reported results for the...